H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Amarin (AMRN) today and set a price target of $51. The company’s shares closed yesterday at $17.52.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 6.0% and a 43.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amarin with a $33.20 average price target, implying an 89.5% upside from current levels. In a report issued on April 18, Cantor Fitzgerald also maintained a Buy rating on the stock with a $35 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.34 and a one-year low of $2.35. Currently, Amarin has an average volume of 7.39M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.
Read More on AMRN:
